The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I dose expansion trial of avelumab (MSB0010718C), an anti-PD-L1 antibody, in Japanese patients with advanced gastric cancer.
 
Yasuhide Yamada
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Dainippon Sumitomo Pharma; Novartis; Pfizer; Taiho Pharmaceutical; Yakult Pharmaceutical
Research Funding - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Merck Serono; Novartis; Otsuka; Taiho Pharmaceutical
 
Tomohiro Nishina
Honoraria - Merck Serono
 
Satoru Iwasa
Honoraria - Chugai Pharma; Takeda
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Lilly (Inst); Merck Serono (Inst); NanoCarrier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Teijin Pharma (Inst)
 
Kohei Shitara
Honoraria - Chugai Pharma; Takeda
Consulting or Advisory Role - Bayer; Chugai Pharma; Lilly Japan
Research Funding - Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Yakult Pharmaceutical (Inst)
 
Kei Muro
Honoraria - Chugai Pharma; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
 
Taito Esaki
Research Funding - Merck Serono (Inst)
 
Shuichi Hironaka
Honoraria - Novartis; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Lilly; Yakult Honsha
 
Kensei Yamaguchi
No Relationships to Disclose
 
Nozomu Machida
No Relationships to Disclose
 
Taroh Satoh
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Merck Serono
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Merck Serono
Research Funding - Chugai Pharma (Inst); Yakult Honsha (Inst)
 
Anja von Heydebreck
Employment - Merck KGaA
Stock and Other Ownership Interests - Merck KGaA
 
Hiroyuki Achiwa
Employment - Merck Serono
 
Toshihiko Doi
Honoraria - Chugai Pharma; Novartis
Consulting or Advisory Role - Amgen; Lilly; Merck Serono; Otsuka
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb Japan (Inst); Eisai (Inst); Janssen (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zenyaku Kogyo (Inst)